AAAAAA
Results: 1-25/32
Authors:
Pericak-Vance, MA
Rimmler, JB
Saunders, AM
Martin, ER
Haines, JL
Garcia, ME
Oksenberg, JR
Barcellos, LF
Lincoln, R
Goodkin, DE
Hauser, SL
Compston, DAS
Sawcer, SJ
Clayton, D
Jones, HB
Walker, N
Goodfellow, PPN
Bulman, D
Sadovnick, D
Ebers, GC
Dyment, D
Willer, C
Risch, N
Citation: Ma. Pericak-vance et al., A meta-analysis of genomic screens in multiple sclerosis, MULT SCLER, 7(1), 2001, pp. 3-11
Authors:
Mohr, DC
Boudewyn, AC
Likosky, W
Levine, E
Goodkin, DE
Citation: Dc. Mohr et al., Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject, ANN BEHAV M, 23(2), 2001, pp. 125-132
Authors:
Ghalie, RG
Goodkin, DE
Citation: Rg. Ghalie et De. Goodkin, Secondary leukemia after adjuvant chemotherapy for breast cancer, J CL ONCOL, 19(4), 2001, pp. 1231-1232
Authors:
Mohr, DC
Goodkin, DE
Islar, J
Hauser, SL
Genain, CP
Citation: Dc. Mohr et al., Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis, ARCH NEUROL, 58(7), 2001, pp. 1081-1086
Authors:
Luks, TL
Goodkin, DE
Nelson, SJ
Majumdar, S
Bacchetti, P
Portnoy, D
Sloan, R
Citation: Tl. Luks et al., A longitudinal study of ventricular volume in early relapsing-remining multiple sclerosis, MULT SCLER, 6(5), 2000, pp. 332-337
Authors:
Suhy, J
Rooney, WD
Goodkin, DE
Capizzano, AA
Soher, BJ
Maudsley, AA
Waubant, E
Andersson, PB
Weiner, MW
Citation: J. Suhy et al., H-1 MRSI comparison of white matter and lesions in primary progressive andrelapsing-remitting MS, MULT SCLER, 6(3), 2000, pp. 148-155
Authors:
Fischer, JS
Priore, RL
Jacobs, LD
Cookfair, DL
Rudick, RA
Herndon, RM
Richert, JR
Salazar, AM
Goodkin, DE
Granger, CV
Simon, JH
Grafman, JH
Lezak, MD
Hovey, KMO
Perkins, KK
Barilla-Clark, D
Schacter, M
Shucard, DW
Davidson, AL
Wende, KE
Bourdette, DN
Kooijmans-Coutinho, MF
Citation: Js. Fischer et al., Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis, ANN NEUROL, 48(6), 2000, pp. 885-892
Authors:
Barcellos, LF
Schito, AM
Rimmler, JB
Vittinghoff, E
Shih, A
Lincoln, R
Callier, S
Elkins, MK
Goodkin, DE
Haines, JL
Pericak-Vance, MA
Hauser, SL
Oksenberg, JR
Citation: Lf. Barcellos et al., CC-chemokine receptor 5 polymorphism and age of onset in familial multiplesclerosis, IMMUNOGENET, 51(4-5), 2000, pp. 281-288
Authors:
Simon, JH
Lull, J
Jacobs, LD
Rudick, RA
Cookfair, DL
Herndon, RM
Richert, JR
Salazar, AM
Sheeder, J
Miller, D
McCabe, K
Serra, A
Campion, MK
Fischer, JS
Goodkin, DE
Simonian, N
Lajaunie, M
Wende, K
Martens-Davidson, A
Kinkel, RP
Munschauer, FE
Citation: Jh. Simon et al., A longitudinal study of T1 hypointense lesions in relapsing MS - MSCRG trial of interferon beta-1a, NEUROLOGY, 55(2), 2000, pp. 185-192
Authors:
Mohr, DC
Goodkin, DE
Bacchetti, P
Boudewyn, AC
Huang, L
Marrietta, P
Cheuk, W
Dee, B
Citation: Dc. Mohr et al., Psychological stress and the subsequent appearance of new brain MRI lesions in MS, NEUROLOGY, 55(1), 2000, pp. 55-61
Authors:
Kita, M
Goodkin, DE
Bacchetti, P
Waubant, E
Nelson, SJ
Majumdar, S
Citation: M. Kita et al., Magnetization transfer ratio in new MS lesions before and during therapy with IFN beta-1a, NEUROLOGY, 54(9), 2000, pp. 1741-1745
Authors:
Goodkin, DE
Shulman, M
Winkelhake, MJ
Waubant, E
Andersson, PB
Stewart, T
Nelson, S
Fischbein, N
Coyle, PK
Frohman, E
Jacobs, L
Holcenberg, J
Lee, M
Mocci, S
Citation: De. Goodkin et al., A phase I trial of solubilized DR2 : MBp(84-102) (AG284) in multiple sclerosis, NEUROLOGY, 54(7), 2000, pp. 1414-1420
Authors:
Mohr, DC
Likosky, W
Bertagnolli, A
Goodkin, DE
Van der Wende, J
Dwyer, P
Dick, LP
Citation: Dc. Mohr et al., Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis, J CONS CLIN, 68(2), 2000, pp. 356-361
Authors:
Kita, M
Goodkin, DE
Citation: M. Kita et De. Goodkin, Drugs used to treat spasticity, DRUGS, 59(3), 2000, pp. 487-495
Authors:
Goodkin, DE
Citation: De. Goodkin, Treatment of progressive forms of multiple sclerosis, MULTIPLE SCLEROSIS: DIAGNOSIS, MEDICAL MANAGEMENT, AND REHABILITATION, 2000, pp. 177-192
Authors:
Mohr, DC
Goodkin, DE
Masuoka, L
Dick, LP
Russo, D
Eckhardt, J
Boudewyn, AC
Bedell, L
Citation: Dc. Mohr et al., Treatment adherence and patient retention in the first year of a Phase-IIIclinical trial for the treatment of multiple sclerosis, MULT SCLER, 5(3), 1999, pp. 192-197
Authors:
Mohr, DC
Goodkin, DE
Citation: Dc. Mohr et De. Goodkin, Treatment of depression in multiple sclerosis: Review and meta-analysis, CL PSYCH-SC, 6(1), 1999, pp. 1-9
Authors:
Goodkin, DE
Reingold, S
Sibley, W
Wolinsky, J
McFarland, H
Cookfair, D
Lublin, F
Citation: De. Goodkin et al., Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: Reporting extended results from Phase III clinical trials, ANN NEUROL, 46(1), 1999, pp. 132-134
Authors:
Mohr, DC
Dick, LP
Russo, D
Likosky, W
Pinn, J
Boudewyn, AC
Goodkin, DE
Citation: Dc. Mohr et al., The psychosocial impact of multiple sclerosis: Exploring the patient's perspective, HEALTH PSYC, 18(4), 1999, pp. 376-382
Authors:
Rudick, RA
Cookfair, DL
Simonian, NA
Ransohoff, RM
Richert, JR
Jacobs, LD
Herndon, RM
Salazar, AM
Fischer, JS
Granger, CV
Goodkin, DE
Simon, JH
Bartoszak, DM
Bourdette, DN
Braiman, J
Brownscheidle, CM
Coats, ME
Cohan, SL
Dougherty, DS
Kinkel, RP
Mass, MK
Munchsauer, FE
O'Reilly, K
Priore, RL
Pullicino, PM
Scherokman, BJ
Wende, K
Weinstock-Guttman, B
Whitham, RH
Citation: Ra. Rudick et al., Cerebrospinal fluid abnormalities in a phase III trial of Avonex (R) (IFN beta-1a) for relapsing multiple sclerosis, J NEUROIMM, 93(1-2), 1999, pp. 8-14
Authors:
Goodkin, DE
Citation: De. Goodkin, Interferon beta treatment for multiple sclerosis - Reply, LANCET, 353(9151), 1999, pp. 498-498
Authors:
Waubant, E
Goodkin, DE
Gee, L
Bacchetti, P
Sloan, R
Stewart, T
Andersson, PB
Stabler, G
Miller, K
Citation: E. Waubant et al., Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis, NEUROLOGY, 53(7), 1999, pp. 1397-1401
Authors:
Waubant, E
Goodkin, DE
Sloan, R
Andersson, PB
Citation: E. Waubant et al., A pilot study of MRI activity before and during interferon beta-1a therapy, NEUROLOGY, 53(4), 1999, pp. 874-876
Authors:
Simon, JH
Jacobs, LD
Campion, MK
Rudick, RA
Cookfair, DL
Herndon, RM
Richert, JR
Salazar, AM
Fischer, JS
Goodkin, DE
Simonian, N
Lajaunie, M
Miller, DE
Wende, K
Martens-Davidson, A
Kinkel, RP
Munschauer, FE
Brownscheidle, CM
Citation: Jh. Simon et al., A longitudinal study of brain atrophy in relapsing multiple sclerosis, NEUROLOGY, 53(1), 1999, pp. 139-148
Authors:
Goodkin, DE
Kinkel, RP
Citation: De. Goodkin et Rp. Kinkel, A phase II study of IV methylprednisolone in secondary progressive MS - Reply, NEUROLOGY, 52(4), 1999, pp. 896-897